{"uid":"cap_FtAhKH2KBctgtWLJ2BQXO","slug":"clinicalintelpulse-deal-signal-m-a-licensing-intelligence-for-b307d08c","name":"ClinicalIntelPulse Deal Signal — M&A & Licensing Intelligence for Clinical Assets","description":"Biotech M&A + licensing deal signal for clinical-stage drugs — Phase 2/3 assets most likely to be acquired or licensed, with acquisition targets, deal comps, transaction multiples and estimated deal values. Worldwide. For biotech-investing and BD agents.","url":"https://clinicalintelpulse.vercel.app/api/clinical/deal-signal","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"stage":{"type":"string"},"condition":{"type":"string"},"deal_type":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}},"responseSchema":{"type":"json","example":{"query_summary":{"as_of":"2026-06-07","stage":"both","condition":"Obesity","deal_type":"both"},"market_context":{"approved_leaders":["Semaglutide (Novo Nordisk — Wegovy)","Tirzepatide (Lilly — Zepbound)"],"big_pharma_strategic_need":"Roche, AstraZeneca, Pfizer, Amgen all need next-gen obesity assets. Roche acquired Carmot Therapeutics for $2.7B. AZ acquired Eccogene for obesity pipeline.","total_addressable_market_usd_bn":100},"recent_deal_comps":[{"deal":"Roche / Carmot Therapeutics","year":2023,"stage":"PHASE1/2","mechanism":"GLP-1 peptide","value_usd_bn":2.7},{"deal":"AstraZeneca / Eccogene","year":2024,"stage":"PHASE2","mechanism":"Small-molecule GLP-1","value_usd_bn":1.85},{"deal":"Amgen / ChemoCentryx","year":2022,"stage":"Approved","mechanism":"C5aR1","value_usd_bn":3.7}],"acquisition_targets":[{"asset":"Mazdutide (IBI362)","risks":["China geopolitical risk for IP transfer","Phase 3 US/EU data needed before deal close"],"stage":"PHASE3","company":"Innovent Biologics (China)","deal_comp":"Structure Day1 Biosciences (Pfizer) $1.25B + milestones — Phase 2 obesity asset. Mazdutide later-stage = premium.","mechanism":"GLP-1/glucagon dual agonist","probability":"High","clinical_data":"Phase 3 China data strong — 14.5% body weight reduction at 52 weeks","deal_rationale":"Ex-China rights available. Differentiated vs. semaglutide on muscle preservation. Lilly or Roche most likely acquirers.","estimated_deal_value_usd_m":"800-2000"}],"deal_timing_signals":"Obesity M&A is peak hot. Big pharma BD teams are actively searching — any Phase 2 readout with >10% weight loss and clean safety profile will attract inbound interest within 3-6 months of data release.","licensing_opportunities":[{"asset":"CT-388 (dual GLP-1/GIP)","notes":"Roche may sublicense ex-US rights to regional partners in Asia/LatAm","company":"Carmot Therapeutics (acq. Roche)","estimated_license_value_usd_m":"300-800"}]}},"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.35","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.35/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.35","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.35","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_rLiWzomLJL58MNVE4Q8m4","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.35","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Returns M&A and licensing deal signals for Phase 2/3 clinical assets, including acquisition probability scores, deal comps, and transaction multiples for a given disease or asset.","exampleAgentPrompt":"Pull the deal signals for Phase 2/3 oncology assets right now — I want to see which ones are most likely to get acquired or licensed, along with transaction multiples and recent deal comps.","exampleUseCases":null,"resultDescription":"A ranked list of Phase 2/3 clinical assets with M&A and licensing probability scores, relevant deal comparables (similar past transactions), and transaction multiples — giving BD and investing agents a structured view of which assets are most likely to attract acquisition or licensing activity.","failureModes":["Disease area or therapeutic category not recognized — returns empty result or 400 error","No active Phase 2/3 assets found for the queried indication — returns empty deal signal list","Payment not processed (x402) — returns 402 Payment Required before data is delivered","Stale deal comps if underlying transaction database has not been recently updated","Rate limiting if too many calls made in short succession"],"whenToPreferThis":"Use this endpoint when an agent needs to identify acquisition or licensing targets among clinical-stage biotech assets, assess deal probability for specific disease areas, or benchmark transaction multiples against historical comps. Prefer this over general pipeline endpoints when the primary goal is business development intelligence or biotech investment screening rather than clinical or scientific analysis.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-15T06:35:08.870Z","isFirstParty":false}